Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted

PLoS Neglected Tropical Diseases

Volumn 11, Issue 2, 2017, Pages

  Nguyen, Thi Huyen Tram ^a,b   Guedj, Jérémie ^a,b   Anglaret, Xavier ^c,d   Laouénan, Cédric ^a,b,e   Madelain, Vincent ^a,b,e   Taburet, Anne Marie ^f,g   Baize, Sylvain ^h   Sissoko, Daouda ^c,i   Pastorino, Boris ^j   Rodallec, Anne ^j   Piorkowski, Géraldine ^j   Carazo, Sara ^k   Conde, Mamoudou N ^l   Gala, Jean Luc ^m,n,o,p   Bore, Joseph Akoi ^q,r,s   Carbonnelle, Caroline ^g   Jacquot, Frédéric ^g   Raoul, Hervé ^g   Malvy, Denis ^c,i   de Lamballerie, Xavier ^j   Mentré, France ^a,b,e   more..

^a UNIVERSITÉ PARIS DIDEROT   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d Programme PACCI site ANRS de Côte d Ivoire   (Côte d’Ivoire)

^e BICHAT HOSPITAL   (France)

^f BICÊTRE HOSPITAL   (France)

^g INSERM   (France)

^h CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

ⁱ BORDEAUX UNIVERSITY HOSPITAL   (France)

^j INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

^k MÉDECINS SANS FRONTIÈRES   (Belgium)

^l Biological Light Fieldable Laboratory for Emergencies ^*  (Senegal)

^m Biological Light Fieldable Laboratory for Emergencies (B LiFE) Belgian First Aid and Support (B FAST)   (Belgium)

ⁿ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^o UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^p Belgian Ministry of Defense   (Belgium)

^q European Mobile Laboratory Consortium   (Germany)

^r INSTITUT NATIONAL DE SANTÉ PUBLIQUE   (Guinea)

^s Guinée Centre de Recherche et de Formation en Infectiologie de Guinée Guinean infectiology research and training center   (Guinea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; FAVIPIRAVIR; HEMOGLOBIN; SODIUM; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BIOLOGICAL MODEL; CHILD; CLINICAL TRIAL (TOPIC); EBOLA HEMORRHAGIC FEVER; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; PREDICTION; PRESCHOOL CHILD; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIREMIA; VIRUS LOAD; YOUNG ADULT; AGED; CLINICAL TRIAL; DRUG EFFECTS; EBOLAVIRUS; FEMALE; GUINEA; HEMORRHAGIC FEVER, EBOLA; MALE; MIDDLE AGED; PHYSIOLOGY; VIROLOGY;

ADOLESCENT; ADULT; AGED; AMIDES; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; EBOLAVIRUS; FEMALE; GUINEA; HEMORRHAGIC FEVER, EBOLA; HUMANS; MALE; MIDDLE AGED; PYRAZINES; YOUNG ADULT;

EID: 85014556774     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0005389     Document Type: Article

References (19)

1. World Health Organization. WHO | Ebola situation reports [Internet]. Available: http://apps.who.int/iris/bitstream/10665/208883/1/ebolasitrep_10Jun2016_eng.pdf?ua=1
2. World Health Organization. Categorization and prioritization of drugs for consideration for testing or use in patients infected with Ebola. In: Ebola treatments and interventions. 3 July 2015 [Internet]. [cited 7 Sep 2015]. Available: http://www.who.int/medicines/ebola-treatment/2015_0703TablesofEbolaDrugs.pdf?ua=1
3. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS, Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res. 2014;104: 153–155. doi: 10.1016/j.antiviral.2014.01.01224462697
4. Oestereich L, Lüdtke A, Wurr S, Rieger T, Muñoz-Fontela C, Günther S, Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105: 17–21. doi: 10.1016/j.antiviral.2014.02.01424583123
5. Madelain V, Nguyen THT, Olivo A, de Lamballerie X, Guedj J, Taburet A-M, et al. Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials. Clin Pharmacokinet. 2016;55: 907–923. doi: 10.1007/s40262-015-0364-126798032
6. Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Report on the Deliberation Results (English version) [Internet]. 4 Mar 2014 [cited 31 May 2016]. Available: https://www.pmda.go.jp/files/000210319.pdf
7. Sissoko D, Laouenan C, Folkesson E, M’Lebing A-B, Beavogui A-H, Baize S, et al. Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. PLoS Med. 2016;13: e1001967. doi: 10.1371/journal.pmed.100196726930627
8. Mentré F, Taburet A-M, Guedj J, Anglaret X, Keïta S, de Lamballerie X, et al. Dose regimen of favipiravir for Ebola virus disease. Lancet Infect Dis. 2015;15: 150–151. doi: 10.1016/S1473-3099(14)71047-325435054
9. Bouazza N, Treluyer J-M, Foissac F, Mentré F, Taburet A-M, Guedj J, et al. Favipiravir for children with Ebola. Lancet. 2015;385: 603–604.
10. Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet A-M, Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. Clin Pharmacokinet. 2010;49: 17–45. doi: 10.2165/11318110-000000000-0000020000887
11. Madelain V, Oestereich L, Graw F, Nguyen THT, de Lamballerie X, Mentré F, et al. Ebola virus dynamics in mice treated with favipiravir. Antiviral Res. 2015;123: 70–77. doi: 10.1016/j.antiviral.2015.08.01526343011
12. Gowen BB, Sefing EJ, Westover JB, Smee DF, Hagloch J, Furuta Y, et al. Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever. Antiviral Res. 2015;121: 132–137. doi: 10.1016/j.antiviral.2015.07.00326186980
13. Gordon AH, Green DE, Subrahmanyan V, Liver aldehyde oxidase. Biochem J. 1940;34: 764–774. 16747217
14. Lobo DN, Stanga Z, Simpson JA, Anderson JA, Rowlands BJ, Allison SP, Dilution and redistribution effects of rapid 2-litre infusions of 0.9% (w/v) saline and 5% (w/v) dextrose on haematological parameters and serum biochemistry in normal subjects: a double-blind crossover study. Clin Sci Lond Engl 1979. 2001;101: 173–179.
15. Marty AM, Jahrling PB, Geisbert TW, Viral hemorrhagic fevers. Clin Lab Med. 2006;26: 345–386, viii. doi: 10.1016/j.cll.2006.05.00116815457
16. Roberts DJ, Hall RI, Drug absorption, distribution, metabolism and excretion considerations in critically ill adults. Expert Opin Drug Metab Toxicol. 2013;9: 1067–1084. doi: 10.1517/17425255.2013.79913723682923
17. Boucher BA, Wood GC, Swanson JM, Pharmacokinetic changes in critical illness. Crit Care Clin. 2006;22: 255–271, vi. doi: 10.1016/j.ccc.2006.02.01116677999
18. Hartmann T, Terao M, Garattini E, Teutloff C, Alfaro JF, Jones JP, et al. The Impact of Single Nucleotide Polymorphisms on Human Aldehyde Oxidase. Drug Metab Dispos. 2012;40: 856–864. doi: 10.1124/dmd.111.04382822279051
19. Madelain V, Guedj J, Mentré F, Nguyen THT, Jacquot F, Oestereich L, et al. Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. Antimicrob Agents Chemother. 2017;61.